Nadolol Clinical Trials

Size	Price	Qty
25mg	USD 147
1g	USD 970

Clinical Trials

Nadolol has been evaluated in numerous clinical trials spanning Early Phase 1 through Phase 4 across diverse cardiovascular and neurological indications, including hypertension, chest pain, variceal bleeding, proliferating infantile hemangiomas, migraines, mild cognitive impairment, and Parkinson's disease dementia. Supported by commercial entities and academic institutions, these studies assess both therapeutic and prophylactic protocols, with overall recruitment statuses encompassing recruiting, completed, and unknown.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06643221	RECRUITING	Leukemia; Hematopoetic Stem Cell Transplantation; Donor Lymphocyte Infusion; CAR T-Cell Therapy; Lymphoma; Cell Therapy	University of Arizona	2018-01-24	EARLY_PHASE1
NCT04739423	COMPLETED	Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia	CuraSen Therapeutics, Inc.	2021-06-28	PHASE2
NCT02505971	COMPLETED	Infantile Hemangioma	The Hospital for Sick Children	2015-09	PHASE3
NCT01804218	UNKNOWN	Mild Persistent Asthma, Uncomplicated	Invion, Inc.	2013-03	PHASE2
NCT01825122	COMPLETED	Smoking Cessation	Invion, Inc.	2014-03	PHASE2
NCT01010308	COMPLETED	Infantile Hemangioma	The Hospital for Sick Children	2009-11	PHASE2
NCT01103154	COMPLETED	Variceal Rebleeding	E-DA Hospital	2005-03	PHASE4
NCT01010308	Completed	Infantile Hemangioma	The Hospital for Sick Children	2009-11	Phase 2
NCT00921349	COMPLETED	Variceal Bleeding; Cirrhosis	National Science and Technology Council, Taiwan	2004-12	PHASE4
NCT00670267	COMPLETED	Asthma	Invion, Inc.	2007-01	PHASE1; PHASE2
NCT00647660	COMPLETED	Healthy	Mylan Pharmaceuticals Inc	2006-07	PHASE1
NCT00648297	COMPLETED	Healthy	Mylan Pharmaceuticals Inc	2006-08	PHASE1
NCT00910689	COMPLETED	Migraine Headache	Ohio University	2001-07	PHASE4
NCT00960245	COMPLETED	High Blood Pressure; Migraine Headaches; Chest Pain	Sandoz	1994-07	PHASE1
NCT00450164	COMPLETED	Gastrointestinal Hemorrhage; Portal Hypertension; Cirrhosis	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	2000-11	PHASE4
NCT00567216	UNKNOWN	Liver Cirrhosis and Hepatoma.; Gastric Variceal Bleeding	Taipei Veterans General Hospital, Taiwan	2007-04	PHASE4
NCT00563602	UNKNOWN	Portal Hypertension; Complications of Cirrhosis	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	2007-08	PHASE4

(data from https://clinicaltrials.gov, updated on 2026-06-05)

Check the Nadolol product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Nadolol functions as a non-selective antagonist of beta-1 and beta-2 adrenergic receptors, competitively inhibiting endogenous catecholamine binding and suppressing adenylyl cyclase activity to diminish downstream cyclic AMP signaling. This blockade reduces heart rate, cardiac contractility, and vascular tone, providing clinical efficacy in reducing high blood pressure and mitigating vascular complications such as variceal bleeding and proliferating infantile hemangioma.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).